Cytosorbents Corporation provided revenue guidance for the full year 2022. They expect continued and progressive improvement in their underlying core non-COVID-19 business in 2022, with growth of 20% or more in 2022 core product sales, compared to $33.8 million in 2021 core sales. They expect limited COVID-19 related sales in 2022 compared to an estimated $6.3 million in COVID-19 related product sales in 2021, as high rates of vaccination and natural immunity have reduced the severity of COVID-19 illness and need for hospitalization and ICU care, and with it the use of CytoSorb in these patients.